STIM trades 492.6% below Wall Street's consensus target of $8.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes STIM achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Neuronetics, Inc. (STIM) has a Wall Street consensus price target of $8.00, based on estimates from 7 covering analysts. With the stock currently trading at $1.35, this represents a potential upside of +492.6%. The company has a market capitalization of $94M.
Analyst price targets range from a low of $8.00 to a high of $8.00, representing a 0% spread in expectations. The median target of $8.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, STIM trades at a trailing P/E of -2.3x. Analysts expect EPS to grow +13.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ELMDElectromed, Inc. | $378M | $45.70 | $38.00 | -16.8% | Buy | 37.6x | 5 |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
ABSIAbsci Corporation | $1.8B | $11.33 | $12.40 | +9.4% | Buy | — | 13 |
LIVNLivaNova PLC | $4.6B | $83.58 | $81.43 | -2.6% | Buy | 19.7x | 15 |
INVAInnoviva, Inc. | $1.6B | $22.25 | $37.00 | +66.3% | Buy | 6.2x | 10 |
GKOSGlaukos Corporation | $8.8B | $150.65 | $153.33 | +1.8% | Buy | — | 24 |
ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
Quick answers to the most common questions about buying STIM stock.
The consensus Wall Street price target for STIM is $8, representing 492.6% upside from the current price of $1.35. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
STIM has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $8 implies 492.6% upside from current levels.
STIM's current price is $1.35 with a consensus target of $8 (492.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $8 for STIM, while the most conservative target is $8. The consensus of $8 represents the median expectation. These targets typically reflect 12-month expectations.
STIM is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month STIM stock forecast based on 7 Wall Street analysts shows a consensus price target of $8, with estimates ranging from $8 (bear case) to $8 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on STIM, with a "Buy" consensus rating and $8 price target (492.6% upside). 5 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
STIM analyst price targets range from $8 to $8, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.